reptides › orforglipron vs semaglutide

orforglipron vs semaglutide

orforglipron (S-tier) vs semaglutide (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

orforglipron — tier S

foundayo. the first non-peptide small-molecule oral GLP-1 receptor agonist. a once-daily pill, no injection, FDA-approved april 2026 for chronic weight management.

a small molecule, not a peptide. the first non-peptide oral GLP-1 receptor agonist to reach FDA approval. eli lilly's once-daily pill, sold as foundayo.

~12.4% ATTAIN-1 wt loss · half-life supports once-daily oral dosing per the FDA-approved label; small-molecule oral absorption without the food/water restrictions of oral peptide GLP-1s · weight loss

semaglutide — tier S

ozempic. wegovy. rybelsus. the GLP-1 drug that made obesity a pharmacology problem.

the GLP-1 that broke containment. ozempic, wegovy, rybelsus. same molecule, three labels.

14.9% STEP 1 wt loss · half-life ~1 week (acylated) · weight loss

at a glance

  • orforglipron: tier S · ~12.4% ATTAIN-1 wt loss
  • semaglutide: tier S · 14.9% STEP 1 wt loss

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.